Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20406077 | 0.85 | P4HTM (0.55) | P4HTMPDGFRBPDGFRALMNACYP1A2 | |
| SCHEMBL24372405 | 0.82 | CD274 (0.60) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL8193168 | 0.82 | P4HTM (0.53) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL1680607 | 0.81 | MAOB (0.59) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL226721 | 0.81 | P4HTM (0.59) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL13571093 | 0.81 | P4HTM (0.55) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL510634 | 0.81 | P4HTM (0.55) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL1974876 | 0.80 | P4HTM (0.58) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| Hydrochloric Acid SCHEMBL2306614 | 0.80 | P4HTM (0.54) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL3944540 | 0.79 | P4HTM (0.57) | P4HTMLMNACYP1A2PTGS1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426246-B1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2024-05-01 | — | — | EP | disclosed |
| CN-108883099-B | Thiazolidinone compounds and use thereof | 石全 | 2021-09-28 | — | — | CN | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| EP-3426246-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | National Health Research Institutes (TW) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017155910-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017155910-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-09-14 | — | — | WO | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-8609699-B2 | Oxotetrahydrofuran-2-yl-benzimidazole derivative | MSD K.K. (JP) | 2013-12-17 | — | — | US | disclosed |
| EP-2328892-B1 | OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20110144162-A1 | OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-2328892-A1 | OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE | MSD K.K. (JP) | 2011-06-08 | — | — | EP | disclosed |
| EP-2018165-B1 | FGF-PECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI AVENTIS (FR) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010024110-A1 | OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-03-04 | — | — | WO | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
| EP-2018165-A1 | FGF-PECEPTOR AGONIST DIMERIC COMPOUNDS | Sanofi-Aventis (FR) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007080325-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144162-A1 | OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE | GCK, GCKR, KHK | P4HTM 1139/4885PDGFRB 2675/4885PDGFRA 2527/4885 |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | OPRL1, OPRD1, OPRK1 | P4HTM 533/4885PDGFRB 1038/4885PDGFRA 1273/4885 |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | P4HTM 639/4885PDGFRB 150/4885PDGFRA 158/4885 |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | OPRL1, OPRD1, OPRK1 | P4HTM 533/4885PDGFRB 1038/4885PDGFRA 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.